|
|
Interlocken Advanced Technology Park, 380 Interlocken Crescent, Suite 780
Broomfield, CO 80021 USA
phone:303.999.3700
fax:303.999.3799
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.accerapharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutic products for neurodegenerative diseases, including Alzheimer's and Parkinson's disease |
|
| Management |
| Steve A. Orndorff, Ph.D., Founder, President and Chief Executive Officer; William T. Poncy, M.B.A., Vice President, Commercial Development; Samuel Henderson, Ph.D., Executive Director, Research; Gregory Kading, CFA, M.B.A., Vice President, Finance; Claude H. Nash, Chairman |
| |
|
|
| |
|
| Keywords |
| biotechnology, nervous, metabolic, imbalances, ketogenic |
|
|
|
| Description |
|
Accera is a private biotechnology company engaged in the discovery and development of therapeutic treatments for neurodegenerative diseases. It has developed a proprietary scientific approach to product development based upon principles of cellular neuroprotection and neuronal metabolism in the brain. |
|
| Products / Services |
The company's pipeline includes therapeutic treatments for Parkinson's disease, Alzheimer's disease and other age-related memory loss disorders. These products are in advanced clinical development where they have demonstrated significant efficacy and improved safety relative to approved drugs in the marketplace.
|
|
| Technology / Differentiation |
| Accera has developed treatments to alleviate both defects in glucose utilization and lipid metabolism resulting from Alzheimer's. These treatments are designed to increase energy to neuronal cells and provide raw materials for cholesterol and acetylcholine synthesis. Accera's revolutionary approach is unique among companies developing treatments for AD. |
|
| Market / Customers |
Accera's product candidates address the high unmet medical need associated with most neurodegenerative diseases (where few, if any, effective therapies exist today). Alzheimer's disease is the most common form of dementia. More than 24 million people currently have dementia and the number will increase to over 80 million by 2040.
|
|
| Status |
| The company will advance its products through Phase II testing and, at the appropriate point of high added-value, establish strategic alliances and partnerships to support commercialization. Accera will expand its pipeline through internal discovery efforts and in-licensing of clinical compounds with novel mechanisms of action. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members